Losartan-induced hypotension leads to tau hyperphosphorylation and memory deficit

J Alzheimers Dis. 2014;40(2):419-27. doi: 10.3233/JAD-131679.

Abstract

Recent studies have reported a correlation between dementia and low blood pressure. How hypotension is associated with the increased risk of Alzheimer's disease (AD) remains unclear. Here we show that one month treatment of losartan, an angiotensin II type 1 (AT1) receptor antagonist, causes chronic and sustained hypotension, along with oxidative stress in adult male Sprague-Dawley rats. Furthermore, we show that losartan treatment increases the level of inactivated protein phosphatase 2A (PP2A) and the hyperphosphorylation of tau at Ser 199 and Ser 396. Rats treated with losartan present memory deficits and decreases in spine-density. These findings suggest that losartan-induced hypotension may increase the risk of AD-like pathological alteration and behavioral impairment through oxidative stress which leads to tau hyperphosphorylation and loss of dendritic spines.

Keywords: Alzheimer's disease; hypotension; losartan; memory deficit; oxidative stress; tau hyperphosphorylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / toxicity*
  • Animals
  • Avoidance Learning / drug effects
  • Blood Pressure / drug effects
  • Dendritic Spines / drug effects
  • Dendritic Spines / pathology
  • Dendritic Spines / ultrastructure
  • Disease Models, Animal
  • Hypertension / chemically induced*
  • Hypertension / pathology
  • Losartan / toxicity*
  • Male
  • Malondialdehyde / metabolism
  • Maze Learning / drug effects
  • Memory Disorders / chemically induced*
  • Memory Disorders / pathology
  • Neurons / drug effects
  • Neurons / pathology
  • Neurons / ultrastructure
  • Oxidative Stress / drug effects
  • Phosphorylation / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Reaction Time / drug effects
  • Superoxide Dismutase / metabolism
  • tau Proteins / metabolism*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • tau Proteins
  • Malondialdehyde
  • Superoxide Dismutase
  • Losartan